tiprankstipranks
Trending News
More News >
Opus Genetics (IRD)
NASDAQ:IRD

Opus Genetics (IRD) AI Stock Analysis

Compare
1,023 Followers

Top Page

IR

Opus Genetics

(NASDAQ:IRD)

44Neutral
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
Positive Factors
Financial Backing
The company's strategic focus is supported by a $20 million public offering and private placement financing, underscoring strong backing for its ongoing projects.
Gene Therapy Progress
Early benefit in visual function and clean safety profile observed in the first patient at Month-1 keeps us optimistic that 3Q25 dataset will better showcase the therapy's potential in this rare indication with high unmet needs.
Strategic Partnerships
The partnership for phentolamine ophthalmic solution, funded by Viatris, adds diversity to the company’s pipeline and offers multiple upcoming data catalysts.
Negative Factors
Increased Expenditures
Our FY25E G&A projection is now at $25mn (up from prior estimate of $14mn), which indicates increased expenditures.
Pipeline Challenges
Presbyopia treatment can gain investor attention with the pivotal Phase 3 VEGA-3 trial of phentolamine ophthalmic solution anticipated to have its topline results, addressing common age-related farsightedness.
Valuation Concerns
Following these updates and accounting for recent dilution, our DCF-based PT is at $5, down from $8.

Opus Genetics (IRD) vs. S&P 500 (SPY)

Opus Genetics Business Overview & Revenue Model

Company DescriptionOpus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
How the Company Makes MoneyOpus Genetics generates revenue primarily through the development and commercialization of its gene therapy products. The company monetizes its innovations by partnering with larger pharmaceutical companies for the co-development and licensing of its therapies. These partnerships often involve upfront payments, milestone payments, and royalties on sales. Additionally, Opus Genetics may receive funding from grants, research collaborations, and venture capital investments to support its research and development efforts.

Opus Genetics Financial Statement Overview

Summary
Opus Genetics is facing significant financial headwinds with declining revenues, persistent losses, and negative cash flows. While the absence of debt is a strength, the company's operational inefficiencies and declining equity raise concerns about its long-term viability. Strategic improvements are necessary to stabilize and improve its financial health.
Income Statement
30
Negative
Opus Genetics shows a volatile revenue trend with significant declines in 2023 and 2024 after a peak in 2022. The company has consistently posted negative net income, indicating persistent unprofitability. The gross profit margin remains high due to the absence of cost of goods sold, but negative EBIT and EBITDA margins highlight ongoing operational challenges.
Balance Sheet
40
Negative
The balance sheet reveals a strong equity position in 2022, which sharply declined in 2023 and 2024 due to accumulated losses. The company has no debt, which is a positive, but the declining stockholders' equity and recent negative equity in 2020 raise concerns about financial stability.
Cash Flow
35
Negative
Operating cash flow has been negative for the past two years, reflecting operational inefficiencies. Free cash flow has worsened significantly in 2024, indicating cash burn issues. The operating cash flow to net income and free cash flow to net income ratios highlight the company's struggle to convert income into cash.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
10.99M19.05M39.85M589.00K0.00
Gross Profit
10.98M19.05M39.85M589.00K0.00
EBIT
-62.07M-10.56M18.23M-22.70M-19.97M
EBITDA
-57.52M-9.97M18.22M-56.69M-17.77M
Net Income Common Stockholders
-57.53M-9.99M17.89M-56.69M-24.62M
Balance SheetCash, Cash Equivalents and Short-Term Investments
30.32M50.52M42.68M24.75M16.40M
Total Assets
36.86M53.95M48.99M26.08M17.68M
Total Debt
0.000.000.00538.00K0.00
Net Debt
-30.32M-50.50M-42.63M-24.00M-16.40M
Total Liabilities
30.14M4.04M2.75M3.85M31.15M
Stockholders Equity
6.72M49.91M46.24M22.22M-13.47M
Cash FlowFree Cash Flow
-25.58M-1.11M14.31M-19.37M-6.80M
Operating Cash Flow
-25.58M-1.11M14.31M-19.37M-6.80M
Investing Cash Flow
1.21M0.000.00-100.00K539.00K
Financing Cash Flow
4.19M8.98M3.79M27.61M21.12M

Opus Genetics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.99
Price Trends
50DMA
0.93
Positive
100DMA
1.03
Negative
200DMA
1.14
Negative
Market Momentum
MACD
0.03
Negative
RSI
60.12
Neutral
STOCH
49.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Positive. The current price of 0.99 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.93, and below the 200-day MA of 1.14, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 49.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRD.

Opus Genetics Risk Analysis

Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Opus Genetics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$57.47M-71.64%-98.90%-177.17%
52
Neutral
$5.19B3.04-44.64%2.82%16.45%-0.53%
48
Neutral
$38.54M10.83-107.28%-71.68%-397.61%
45
Neutral
$51.97M-232.51%138.11%76.60%
IRIRD
44
Neutral
$60.26M-229.30%-42.30%-330.51%
35
Underperform
$52.15M-81.44%16.38%
34
Underperform
$35.91M-49.32%38.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IRD
Opus Genetics
0.99
-0.74
-42.77%
SPRO
Spero Therapeutics
0.69
-0.82
-54.30%
CELU
Celularity
2.17
-0.85
-28.15%
RPTX
Repare Therapeutics
1.38
-2.02
-59.41%
PRLD
Prelude Therapeutics
0.98
-3.11
-76.04%
ANTX
AN2 Therapeutics, Inc.
1.19
-0.97
-44.91%

Opus Genetics Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Opus Genetics Terminates Purchase Agreement with Lincoln Park
Negative
Apr 4, 2025

On April 2, 2025, Opus Genetics, Inc. announced the termination of its Purchase Agreement with Lincoln Park Capital Fund, LLC, which was initially established on August 10, 2023. The decision was influenced by current market dynamics, particularly the limited value of the facility due to the current market price of the company’s stock. Prior to the termination, Opus Genetics had issued 1,700,000 shares, generating approximately $5.2 million in net proceeds, leaving about $44.8 million in shares unsold under the agreement.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.